122 related articles for article (PubMed ID: 11860413)
1. Nizatidine and cisapride enhance salivary secretion in humans.
Adachi K; Ono M; Kawamura A; Yuki M; Fujishiro H; Kinoshita Y
Aliment Pharmacol Ther; 2002 Feb; 16(2):297-301. PubMed ID: 11860413
[TBL] [Abstract][Full Text] [Related]
2. Nizatidine and cisapride increase salivary secretion in rats.
Adachi K; Furuta K; Katsube T; Fujisawa T; Azumi T; Fujishiro H; Ishihara S; Amano Y; Kinoshita Y
Dig Dis Sci; 2004 Mar; 49(3):399-403. PubMed ID: 15139487
[TBL] [Abstract][Full Text] [Related]
3. Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat.
Ueki S; Matsunaga Y; Yoneta T; Tamaki H; Itoh Z
Arzneimittelforschung; 1999 Jul; 49(7):618-25. PubMed ID: 10442211
[TBL] [Abstract][Full Text] [Related]
4. Nizatidine enhances salivary secretion in patients with dry mouth.
Nin T; Umemoto M; Negoro A; Miuchi S; Sakagami M
Auris Nasus Larynx; 2008 Jun; 35(2):224-9. PubMed ID: 18082986
[TBL] [Abstract][Full Text] [Related]
5. Effects of cisapride on salivary production in normal subjects.
Patel R; Launspach J; Soffer E
Dig Dis Sci; 1996 Mar; 41(3):480-4. PubMed ID: 8617119
[TBL] [Abstract][Full Text] [Related]
6. Weakening effect of famotidine but not of nizatidine on the mucus-bicarbonate barrier of the human stomach.
Guslandi M; Battaglia A; Pamparana F; Passaretti S; Pellegrini A; Tittobello A
Drugs Exp Clin Res; 1990; 16(9):481-5. PubMed ID: 1983112
[TBL] [Abstract][Full Text] [Related]
7. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
Goldin GF; Marcinkiewicz M; Zbroch T; Bityutskiy LP; McCallum RW; Sarosiek J
Dig Dis Sci; 1997 Jul; 42(7):1362-9. PubMed ID: 9246029
[TBL] [Abstract][Full Text] [Related]
8. The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease.
Orr WC; Chen CL; Sloan S
Aliment Pharmacol Ther; 2001 Sep; 15(9):1385-8. PubMed ID: 11552909
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of bicarbonate secretion by the human oesophagus.
Mertz-Nielsen A; Hillingsø J; Bukhave K; Rask-Madsen J
Gut; 1997 May; 40(5):582-6. PubMed ID: 9203933
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of salivary esophagoprotection: rationale for a physiological approach to gastroesophageal reflux disease.
Sarosiek J; Scheurich CJ; Marcinkiewicz M; McCallum RW
Gastroenterology; 1996 Mar; 110(3):675-81. PubMed ID: 8608875
[TBL] [Abstract][Full Text] [Related]
11. Impact of smoking cessation on salivary function in healthy volunteers.
Trudgill NJ; Smith LF; Kershaw J; Riley SA
Scand J Gastroenterol; 1998 Jun; 33(6):568-71. PubMed ID: 9669624
[TBL] [Abstract][Full Text] [Related]
12. Salivary function in patients with reflux esophagitis: effect of cisapride.
Chen SD; Kao CH; Chang CS; Chen GH
J Nucl Med; 1998 Aug; 39(8):1449-52. PubMed ID: 9708526
[TBL] [Abstract][Full Text] [Related]
13. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine.
Mescheder A; Ebert U; Halabi A; Kirch W
Eur J Clin Pharmacol; 1993; 45(2):151-6. PubMed ID: 8223837
[TBL] [Abstract][Full Text] [Related]
14. Gastric acid and salivary bicarbonate. Is there a relationship in duodenal ulcer patients?
Namiot Z; Stasiewicz J; Markowski AR; Namiot DB; Jaroszewicz W; Kemona A; Górski J
Rocz Akad Med Bialymst; 2004; 49():75-9. PubMed ID: 15631318
[TBL] [Abstract][Full Text] [Related]
15. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
Gardner JD; Rodriguez-Stanley S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2002 Oct; 16(10):1819-29. PubMed ID: 12269977
[TBL] [Abstract][Full Text] [Related]
16. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats.
Ueki S; Seiki M; Yoneta T; Aita H; Chaki K; Hori Y; Morita H; Tagashira E; Itoh Z
J Pharmacol Exp Ther; 1993 Jan; 264(1):152-7. PubMed ID: 8093722
[TBL] [Abstract][Full Text] [Related]
17. A distinct salivary secretory response mediated by the esophago-salivary reflex in patients with Barrett's esophagus: its potential pathogenetic implications.
Yandrapu H; Marcinkiewicz M; Poplawski C; Namiot Z; Zbroch T; Sarosiek J
Adv Med Sci; 2014 Sep; 59(2):281-7. PubMed ID: 25181642
[TBL] [Abstract][Full Text] [Related]
18. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Fullarton GM; Macdonald AM; McColl KE
Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.
Hansen JM; Bytzer P; Schaffalitzky de Muckadell OB
Am J Gastroenterol; 1998 Mar; 93(3):368-74. PubMed ID: 9517642
[TBL] [Abstract][Full Text] [Related]
20. Nizatidine enhances the gastrocolonic response and the colonic peristaltic reflex in humans.
Sun WM; Hasler WL; Lien HC; Montague J; Owyang C
J Pharmacol Exp Ther; 2001 Oct; 299(1):159-63. PubMed ID: 11561075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
